welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Earlier start of corticosteroids in DMD linked to earlier heart disease onset, study suggests
Researchers say it is important to carefully assess the timing of the start of corticosteroid treatment for Duchenne muscular dystrophy (DMD) in children and its potential association with disease outcomes.
The study, “Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy,” was published in the journal Neuromuscular Disorders.
DMD is an inherited childhood-onset disease characterized by mutations in the DMD gene that provides instructions for making a protein called dystrophin, located primarily in skeletal muscles used for movement and in the heart muscle. These mutations lead to progressive muscle weakness.
rareRelated
-
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenn...Background:Corticosteroid treatment is c...
-
Corticosteroid treatment and growth patterns in ambulatory males with Duchenne Muscular DystrophyObjectives: To evaluate growth patterns...
-
Steroid use in duchenne: Expert dialogue on latest dataHealthcare professionals, personal careg...
-
Effect of Deflazacort and Prednisone Versus Placebo on Pulmonary Function in Boys with Duchenne Muscular Dystrophy W...Objective: To prospectively assess the ...
-
Neurodevelopmental Needs in Young Boys with Duchenne Muscular Dystrophy (DMD): Observations from the Cooperative Int...Introduction: Duchenne muscular dystroph...
-
Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular DystrophyWhile it has been known for many years t...
-
PTC Therapeutics Announces Publication of Data Demonstrating the Clinical Differentiated Benefit of DeflazacortPTC Therapeutics, Inc. today announced t...
